Abstract:There is a growing interest in the discovery of novel xanthine oxidase inhibitors for gout prevention and treatment with fewer side effects. This study aimed to identify the xanthine oxidase (XO) inhibitory potential and drug-likeness of the metabolites present in the methanolic leaf extract of Anastatica (A.) hierochuntica L. using in vitro and in silico models. The extract-derived metabolites were identified by liquid-chromatography-quadrupole-time-of-flight-mass-spectrometry (LC-QTOF-MS). Molecular docking predicted the XO inhibitory activity of the identified metabolites and validated the best scored in vitro XO inhibitory activities for experimental verification, as well as predictions of their anticancer, pharmacokinetic, and toxic properties; oral bioavailability; and endocrine disruption using SwissADMET, PASS, ProTox-II, and Endocrine Disruptome web servers. A total of 12 metabolites, with a majority of flavonoids, were identified. Rutin, quercetin, and luteolin flavonoids demonstrated the highest ranked docking scores of -12.39, -11.15, and -10.43, respectively, while the half-maximal inhibitory concentration (IC50) values of these metabolites against XO activity were 11.35 µM, 11.1 µM, and 21.58 µM, respectively. In addition, SwissADMET generated data related to the physicochemical properties and drug-likeness of the metabolites. Similarly, the PASS, ProTox-II, and Endocrine Disruptome prediction models stated the safe and potential use of these natural compounds. However, in vivo studies are necessary to support the development of the prominent and promising therapeutic use of A. hierochuntica methanolic-leaf-extract-derived metabolites as XO inhibitors for the prevention and treatment of hyperuricemic and gout patients. Furthermore, the predicted findings of the present study open a new paradigm for these extract-derived metabolites by revealing novel oncogenic targets for the potential treatment of human malignancies.

First Identification of Xanthone Sulfonamides As Potent Acyl-Coa:Cholesterol Acyltransferase (ACAT) Inhibitors.

Synthesis, biological evaluation, and molecular docking studies of xanthone sulfonamides as ACAT inhibitors.

Discovery of Novel N,N-3-phenyl-3-benzylaminopropionanilides As Potent Inhibitors of Cholesteryl Ester Transfer Protein in Vivo.

Design, Synthesis and Biological Evaluation of N,N-3-phenyl-3-benzylaminopropanamide Derivatives As Novel Cholesteryl Ester Transfer Protein Inhibitor

Discovery of selective ACAT2 antagonist via a combination strategy based on deep docking, pharmacophore modelling, and molecular dynamics simulation

Lipid Accumulation Inhibitory Activities of Novel Isoxazole-Based Chenodeoxycholic Acids: Design, Synthesis and Preliminary Mechanism Study

Design and Synthesis of Further Simplified Pyripyropene A Based ACAT2 Selective Inhibitors

Design, Synthesis and Biological Evaluation of Novel Chroman Derivatives As Non-Selective Acetyl-Coa Carboxylase Inhibitors

Lipid reducing activity of novel cholic acid (CA) analogs: Design, synthesis and preliminary mechanism study.

Combined Omics Approach Identifies Gambogic Acid and Related Xanthones As Covalent Inhibitors of the Serine Palmitoyltransferase Complex

Discovery and characterization of novel ATP citrate lyase inhibitors from Acanthopanax senticosus (Rupr. & Maxim.) Harms

Discovery of Flavonoids As Novel Inhibitors of ATP Citrate Lyase: Structure–Activity Relationship and Inhibition Profiles

Synthesis and Evaluation of Novel Xanthone Derivatives As Potent Ache Inhibitors

Discovery, Synthesis and Evaluation of Novel Cholesterol Absorption Inhibitors

Discovery of Anti-Hypercholesterolemia Agents Targeting LXRα from Marine Microorganism-Derived Natural Products

Discovery of Tissue Selective Liver X Receptor Agonists for the Treatment of Atherosclerosis Without Causing Hepatic Lipogenesis.

Synthesis and Biological Evaluation of 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors

1,3,4-Oxadiazoline derivatives as novel potential inhibitors targeting chitin biosynthesis: design, synthesis and biological evaluation.

Identification of Anastatica hierochuntica L. Methanolic-Leaf-Extract-Derived Metabolites Exhibiting Xanthine Oxidase Inhibitory Activities: In Vitro and In Silico Approaches

Design, synthesis, and evaluation of chalcone derivatives as xanthine oxidase inhibitors

Discovery of Novel N-Hydroxy-1,2,4-oxadiazole-5-formamides As ASM Direct Inhibitors for the Treatment of Atherosclerosis